Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages

Abdel-Aziz, Azza; Ahmed, Rehab Allah; Ibrahiem, Afaf T.

doi:10.1016/j.anndiagpath.2017.05.003

Cited by 11 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also confirmed that B7H5 expression correlation with Ki67 expression in patients with GC ( P = .003); Ki67 expression was detected in patients with GC with high B7H5 expression. Ki67 is an antigen associated with proliferation, and overexpression of Ki67 is negatively correlated with carcinoma differentiation . It further revealed that high B7H5 expression predicted poor outcome in patients with GC.…”

Section: Discussionmentioning

confidence: 91%

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Chen

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignancy with low 5-year overall survival (OS).Recently, immune therapy has been used to treat cancer. B7H5 and CD28H are novel immune checkpoint molecules. However, the prognostic value of B7H5/CD28H expression in patients with GC remains unclear. In this study, seventy-one patients diagnosed with GC were included in this study. Patients' GC tissues and matched adjacent tissue constructed a tissue microarray. The expression levels of B7H5 and CD28H were examined using immunohistochemistry. Correlations between the expression of B7H5 and CD28H and the clinical data were evaluated. We found that the expression of B7H5 and CD28H (both P = .001) were higher in GC tumour tissues than in adjacent noncancerous tissues. B7H5/CD28H expression acted as an independent predictive factor in the OS of patients with GC. High expression of B7H5 and CD28H predicted poor outcome.Patients in the B7H5+CD28H+ group had a lower 5-year OS compared with patients in the B7H5−CD28− group (4.5% vs 55.6%, P = .001). A significant difference was found in the 5-year OS between patients in the B7H5+CD28H− and B7H5+CD28H+ groups (33.5% vs 4.5%, P = .006). However, there was no correlation between B7H5 and CD28H expression (P = .844). Therefore, B7H5 and CD28H expression are up-regulated in GC and are independent prognostic factors for overall survival in patients with GC. Although there was no correlation between B7H5 and CD28H expression, high expression of B7H5 and CD28H predicts poor prognosis, especially when both are highly expressed. K E Y W O R D SB7 family checkpoints, B7H5, CD28H, gastric cancer, immunotherapy

show abstract

Section: Discussionmentioning

confidence: 91%

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Chen

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…All of the studies were retrospective. Of all of the studies, 24 were performed in China 24-47, 12 in Japan 48-59, 3 in Greece 60-62 , 2 in Italy 63, 64, 2 in Poland 65, 66, 1 in Korea 67, 1in Germany 68, 2 in Egypt 69, 70, 1 in Finland 71, 1 in Timisoara 72, 1 in Turkey 73, 1 in Sultanate of Oman 74, 1 in Tunisia 75 and 1 in Saudi Arabia 76. A total of 10 publications were written in Chinese and 43 articles were written in English.…”

Section: Resultsmentioning

confidence: 99%

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

Xiong¹,

Zeng²,

Jiang³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Gastric cancer (GC) threatens human health worldwide and we performed this meta-analysis to evaluate the clinical value of Ki-67/MKI67 in patients with GC. The combined hazard ratio (HR), odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relationships of Ki-67/MKI67 expression with prognoses and clinicopathological characteristics. Genes co-expressed with MKI67 were collected for Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) network analyses. In total, 53 studies with 7078 patients were included in this study. The pooled HRs indicated that an elevated expression of Ki-67/MKI67 predicted an unfavorable overall survival (HR: 1.54, 95% CI: 1.33-1.78, P<0.0001) and disease-free survival (HR: 2.28, 95% CI: 1.43-3.64, P<0.0001) in GC patients. Additionally, in patients with advanced GC, a high Ki-67/MKI67 expression was also significantly connected with OS (HR: 1.37, 95% CI: 1.18-1.60, P<0.0001). The combined ORs showed that Ki-67/MKI67 expression was related to TNM stage (stage III/IV versus stage I/II: OR=1.93, 95% CI=1.34-2.78, P<0.0001), tumor differentiation (poor versus well/moderate: OR=1.94, 95% CI=1.32-2.85, P=0.001), lymph node metastasis (yes versus no: OR=1.67, 95% CI=1.23-2.25, P=0.001), distant metastasis (yes versus no: OR=1.67, 95% CI=1.24-2.26, P=0.001) and tumor invasion depth (T3/T4 versus Tis/T1/T2: OR=1.98, 95% CI=1.60-2.44, P<0.0001). The results of GO, KEGG pathway and PPI network analyses indicated that Ki-67/MKI67 may be involved in the development of GC via influencing P53 signaling pathway. Ki-67/MKI67 could be a potential indicator to predict the prognosis of patients with GC and identify high-risk cases. Detecting Ki-67/MKI67 expression in clinic may be helpful in optimizing individual treatment and further improving the survival expectancy of patients with GC.

show abstract

“…Out of 28 patients tested, only four were HER-2 overexpressed by IHC, representing 9.8%. This represents one of the lowest reported HER-2 positivity in patients with metastatic GC [ 19 ]. Patients with treated HER-2-positive GC have improved survival compared to the HER-2-negative group.…”

Section: Discussionmentioning

confidence: 99%

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience

Aseafan¹,

Gad²,

Alshamsan³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background Gastric cancer (GC) carries a poor survival outcome despite the availability of many therapeutic agents active in treatment. In this study, we aimed to evaluate the survival outcomes of metastatic GC treatment from a single center in Saudi Arabia and identify possible prognostic factors. Methodology Data on patients diagnosed with metastatic GC between December 2009 and November 2013 were collected and analyzed. Results During this period, 41 patients were diagnosed with a median age at diagnosis of 52 years, and 56.1% of patients were males. Only four (9.2%) patients had human epidermal growth factor receptor 2 overexpression. Overall, 83% were treated with oxaliplatin-based chemotherapy. The median progression-free survival (PFS) and overall survival (OS) were 4.1 and 15.4 months, respectively. Female sex was an independent prognostic factor for better PFS and OS. Normal lymphocyte count was associated with improved PFS. Conclusions Our study highlights poor outcomes in patients with metastatic GC and the need for further research in this field.

show abstract

Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages

Cited by 11 publications

References 30 publications

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience

Contact Info

Product

Resources

About